NEW YORK (Reuters Health) Jul 05 –
In the treatment of type 2 diabetes with pioglitazone (Actos; Takeda Pharmaceuticals), improvement in glycemic control and insulin sensitivity is associated with a shift in the distribution of fat from visceral to subcutaneous adipose depots.
Dr. Yoshinori Miyazaki and colleagues from the University of Texas Health Science Center in San Antonio report the findings in the June issue of The Journal of Clinical Endocrinology and Metabolism. They believe this is the first study to look at the relationship between changes in abdominal fat distribution, glucose homeostasis, and insulin sensitivity after thiazolidinedione treatment in type 2 diabetics.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!